For nearly every type of disease, a portfolio of tests that deliver accurate, clinically relevant results, at all access points for patient testing.
Would you like more details? Our expert-led virtual demonstrations will give you additional insights you can bring back to your organization.
Providing the Clinical Excellence You Expect
Siemens Healthineers provides you with a broad portfolio of tests to help your lab deliver accurate, trusted results, at all access points for patient testing. From STAT tests in the ED to A1c monitoring and detecting SARS-CoV-2 immune response, we offer a broad menu of over 200 high-performing assays to help support improved clinical outcomes.
Siemens Healthineers is proud to offer our SARS-CoV-2 Total and IgG antibody assays, in addition to real-time PCR testing, to aid in establishing a full picture of the impact of SARS-CoV-2.
Siemens Healthineers offers proven, true high-sensitivity cardiac troponin I assays that provide fast, accurate, and actionable test results. Available on the Atellica® IM Analyzer, the ADVIA Centaur® System, and the Dimension® EXL™ and Dimension Vista® Systems.
The Atellica IM B·R·A·H·M·S PCT Assay helps achieve early sepsis risk assessment and aids in the management of antibiotic therapy to support the ability to make confident decisions for reduced morbidity and mortality.
Every minute counts when diagnosing and treating overdoses. Siemens Healthineers offers a full drug screening portfolio of over 50 drugs of abuse and therapeutic drug monitoring assays, including Fentanyl, Tramadol, Buprenorphine, and Oxycodone.
2020 AACC Scientific Posters
Our scientific posters cover relevant topics that represent Siemens Healthineers breadth of menu, from innovative assay studies to performance evaluations of our laboratory and point-of-care testing solutions
Product availability may vary from country and is subject to local regulatory requirements.
New and Novel Assays
†ELF Test under FDA review. Not available for sale in the U.S.
1. Sigma Metrics for Atellica Solution Assays White Paper. Based on IFU data.
1. New plasma claims for eight assays are completed for ADVIA Centaur XP/XPT/CP Systems and Atellica Analyzers. Plasma claims for additional 12 assays are in development. Future availability cannot be guaranteed.